Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

Trial Profile

Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs Ezetimibe (Primary)
  • Indications Hypertriglyceridaemia; Low HDL cholesterol
  • Focus Pharmacodynamics
  • Acronyms EZEmRNA
  • Most Recent Events

    • 11 Apr 2016 Status changed from recruiting to completed.
    • 31 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 31 Mar 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top